[go: up one dir, main page]

WO2008105462A1 - ヘルパーｔ細胞の活性化方法およびそのための組成物 - Google Patents

ヘルパーｔ細胞の活性化方法およびそのための組成物 Download PDF

Info

Publication number
WO2008105462A1
WO2008105462A1 PCT/JP2008/053417 JP2008053417W WO2008105462A1 WO 2008105462 A1 WO2008105462 A1 WO 2008105462A1 JP 2008053417 W JP2008053417 W JP 2008053417W WO 2008105462 A1 WO2008105462 A1 WO 2008105462A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
helper
composition
activation
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/053417
Other languages
English (en)
French (fr)
Inventor
Haruo Sugiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Institute of Cancer Immunology Inc
Original Assignee
International Institute of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HK10104389.9A priority Critical patent/HK1138321B/en
Priority to ES08712039.0T priority patent/ES2559062T3/es
Priority to NZ578721A priority patent/NZ578721A/en
Priority to DK08712039.0T priority patent/DK2119778T3/en
Priority to CA2677075A priority patent/CA2677075C/en
Priority to MX2014002596A priority patent/MX352947B/es
Priority to JP2009501276A priority patent/JP5225262B2/ja
Priority to MX2009009168A priority patent/MX2009009168A/es
Priority to UAA200909812A priority patent/UA101608C2/uk
Priority to HRP20160020TT priority patent/HRP20160020T1/hr
Priority to BRPI0808084-4A priority patent/BRPI0808084A2/pt
Application filed by International Institute of Cancer Immunology Inc filed Critical International Institute of Cancer Immunology Inc
Priority to AU2008220031A priority patent/AU2008220031B2/en
Priority to SI200831564T priority patent/SI2119778T1/sl
Priority to EP08712039.0A priority patent/EP2119778B1/en
Priority to US12/449,765 priority patent/US10139395B2/en
Priority to PL08712039T priority patent/PL2119778T3/pl
Publication of WO2008105462A1 publication Critical patent/WO2008105462A1/ja
Priority to IL200161A priority patent/IL200161A/en
Anticipated expiration legal-status Critical
Priority to US16/163,682 priority patent/US11555814B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)

Abstract

　本発明は、ＷＴ１ペプチドを抗原提示細胞に添加して、ヘルパーＴ細胞を活性化する工程を含む、ヘルパーＴ細胞の活性化方法であって、該ＷＴ１ペプチドがＨＬＡ－ＤＲＢ１＊１５０１分子、ＨＬＡ－ＤＰＢ１＊０９０１分子、またはＨＬＡ－ＤＰＢ１＊０５０１分子のいずれかに結合する能力を有するものである方法およびそのための組成物、ヘルパーＴ細胞を活性化することによる癌の治療および／または予防方法およびそのための医薬組成物などに関するものである。
PCT/JP2008/053417 2007-02-27 2008-02-27 ヘルパーｔ細胞の活性化方法およびそのための組成物 Ceased WO2008105462A1 (ja)

Priority Applications (18)

Application Number Priority Date Filing Date Title
BRPI0808084-4A BRPI0808084A2 (pt) 2007-02-27 2008-02-27 Método para ativação de células t auxiliadoras e composição para uso no método.
NZ578721A NZ578721A (en) 2007-02-27 2008-02-27 Method for activation of helper t cell and composition for use in the method
DK08712039.0T DK2119778T3 (en) 2007-02-27 2008-02-27 A process for the activation of the helper T cell, and composition for use in this process
CA2677075A CA2677075C (en) 2007-02-27 2008-02-27 Method for activation of helper t cell and composition for use in the method
MX2014002596A MX352947B (es) 2007-02-27 2008-02-27 Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
JP2009501276A JP5225262B2 (ja) 2007-02-27 2008-02-27 ヘルパーｔ細胞の活性化方法およびそのための組成物
MX2009009168A MX2009009168A (es) 2007-02-27 2008-02-27 Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
UAA200909812A UA101608C2 (uk) 2007-02-27 2008-02-27 Спосіб активації хелперних t-клітин
AU2008220031A AU2008220031B2 (en) 2007-02-27 2008-02-27 Method for activation of helper T cell and composition for use in the method
HK10104389.9A HK1138321B (en) 2007-02-27 2008-02-27 Method for activation of helper t cell and composition for use in the method
ES08712039.0T ES2559062T3 (es) 2007-02-27 2008-02-27 Método para la activación de linfocitos T colaboradores y composición para su uso en el método
HRP20160020TT HRP20160020T1 (hr) 2007-02-27 2008-02-27 Postupak za aktiviranje pomagaäśke t stanice i pripravak za uporabu u postupku
SI200831564T SI2119778T1 (sl) 2007-02-27 2008-02-27 Postopek aktivacije celice T pomagalke in sestavek za uporabo postopka
EP08712039.0A EP2119778B1 (en) 2007-02-27 2008-02-27 Method for activation of helper T cell and composition for use in the method
US12/449,765 US10139395B2 (en) 2007-02-27 2008-02-27 Method for activation of helper T cell and composition for use in the method
PL08712039T PL2119778T3 (pl) 2007-02-27 2008-02-27 Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
IL200161A IL200161A (en) 2007-02-27 2009-07-30 METHOD AND ACTIVATION OF ASSISTED T cell and compound for method use
US16/163,682 US11555814B2 (en) 2007-02-27 2018-10-18 Method for activation of helper t cell and composition for use in the method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007047317 2007-02-27
JP2007-047317 2007-02-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/449,765 A-371-Of-International US10139395B2 (en) 2007-02-27 2008-02-27 Method for activation of helper T cell and composition for use in the method
US16/163,682 Division US11555814B2 (en) 2007-02-27 2018-10-18 Method for activation of helper t cell and composition for use in the method

Publications (1)

Publication Number Publication Date
WO2008105462A1 true WO2008105462A1 (ja) 2008-09-04

Family

ID=39721287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053417 Ceased WO2008105462A1 (ja) 2007-02-27 2008-02-27 ヘルパーｔ細胞の活性化方法およびそのための組成物

Country Status (25)

Country Link
US (2) US10139395B2 (ja)
EP (1) EP2119778B1 (ja)
JP (2) JP5225262B2 (ja)
KR (1) KR101598228B1 (ja)
CN (6) CN104774910B (ja)
AU (1) AU2008220031B2 (ja)
BR (1) BRPI0808084A2 (ja)
CA (1) CA2677075C (ja)
CY (1) CY1117150T1 (ja)
DK (1) DK2119778T3 (ja)
ES (1) ES2559062T3 (ja)
HR (1) HRP20160020T1 (ja)
HU (1) HUE027472T2 (ja)
IL (1) IL200161A (ja)
MX (2) MX352947B (ja)
MY (2) MY164867A (ja)
NZ (3) NZ578721A (ja)
PL (1) PL2119778T3 (ja)
PT (1) PT2119778E (ja)
RU (2) RU2680539C2 (ja)
SG (1) SG177998A1 (ja)
SI (1) SI2119778T1 (ja)
UA (1) UA101608C2 (ja)
WO (1) WO2008105462A1 (ja)
ZA (1) ZA200905467B (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010123065A1 (ja) * 2009-04-23 2010-10-28 株式会社癌免疫研究所 癌抗原ヘルパーペプチド
WO2012046730A1 (ja) 2010-10-05 2012-04-12 国立大学法人大阪大学 ヘルパーｔ細胞の活性化方法
WO2014042226A1 (ja) 2012-09-12 2014-03-20 株式会社癌免疫研究所 抗原特異的ヘルパーｔ細胞レセプター遺伝子
WO2014098012A1 (ja) 2012-12-17 2014-06-26 大塚製薬株式会社 ヘルパーt細胞の活性化方法
WO2015129790A1 (ja) * 2014-02-26 2015-09-03 株式会社バイオイミュランス Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤
US10124046B2 (en) 2003-11-05 2018-11-13 International Institute Of Cancer Immunology, Inc. HLA-DR-binding antigen peptide derived from WT1
US10139395B2 (en) 2007-02-27 2018-11-27 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
CA2783550A1 (en) 2009-12-08 2011-06-16 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US9851356B2 (en) 2011-09-14 2017-12-26 International Institute Of Cancer Immunology, Inc. Method for measuring anti-WT1 antibody
EP2792745B1 (en) * 2011-12-14 2017-11-15 National University Corporation Kochi University Modification of helper t cell-inducing polypeptide
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN105377291B (zh) 2013-01-15 2019-04-02 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
JP6770269B2 (ja) 2015-06-25 2020-10-14 国立大学法人神戸大学 経口腫瘍ワクチン
CN110214028A (zh) 2016-12-26 2019-09-06 国立大学法人神户大学 联合使用口服肿瘤疫苗和免疫抑制阻滞剂的癌症治疗
IL294290A (en) 2019-12-31 2022-08-01 Elixirgen Therapeutics Inc Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
KR102647825B1 (ko) * 2021-07-22 2024-03-14 서울대학교산학협력단 항-hla-dp 단클론 항체 및 이의 용도
CN116559462A (zh) * 2023-04-12 2023-08-08 中国科学技术大学 用于肿瘤患者预后的生物标志物组及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2005045027A1 (ja) 2003-11-05 2005-05-19 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
WO2005095598A1 (ja) 2004-03-31 2005-10-13 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来の癌抗原ペプチド
WO2007097358A1 (ja) 2006-02-22 2007-08-30 International Institute Of Cancer Immunology, Inc. Ｈｌａ－ａ＊３３０３拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
AU6407899A (en) * 1998-09-30 2000-04-17 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
AU2001247220A1 (en) 2000-02-22 2001-09-03 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
ATE383375T1 (de) 2001-03-22 2008-01-15 Int Inst Cancer Immunology Inc Wti-modifiziertes peptid
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
DE60238958D1 (de) 2001-06-29 2011-02-24 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem Krebs-Antigen auf Grundlage des Produkts aus dem Tumorunterdrückungsgen WT1 und einem kationischen Liposom
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028757A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
EP1447092A4 (en) 2001-09-28 2007-07-11 Haruo Sugiyama METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
EP1550453B1 (en) 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
ES2331305T3 (es) 2002-09-20 2009-12-29 International Institute Of Cancer Immunology, Inc. Peptidos de wt1 de tipo sustituido.
BRPI0406800B8 (pt) 2003-01-15 2021-05-25 Chugai Seiyaku Kk Chugai Pharmaceutical Co Ltd "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
EP2343083B1 (en) 2003-06-27 2014-01-15 International Institute of Cancer Immunology, Inc. Method of diagnosing cancer comprising the measurement of WT1-specific CTL precursor cells
JP2007516966A (ja) * 2003-12-01 2007-06-28 スローン−ケターリング インスティチュート フォー キャンサー リサーチ 合成ｈｌａ結合ペプチド類似体及びその使用方法
JP4719876B2 (ja) * 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
DE602006017880D1 (ja) 2005-11-30 2010-12-09 Chugai Pharmaceutical Co Ltd
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
CN101573448B (zh) 2006-12-28 2012-07-11 株式会社癌免疫研究所 Hla-a*1101限制的wt1肽及含有其的药物组合物
WO2008105462A1 (ja) 2007-02-27 2008-09-04 International Institute Of Cancer Immunology, Inc. ヘルパーｔ細胞の活性化方法およびそのための組成物
EP3173480A3 (en) 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
AR076349A1 (es) * 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
CA2813557C (en) 2010-10-05 2021-05-04 Otsuka Pharmaceutical Co., Ltd. Method for activating helper t cell
SG11201504530VA (en) 2012-12-17 2015-07-30 Otsuka Pharma Co Ltd Method for activating helper t cell

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2005045027A1 (ja) 2003-11-05 2005-05-19 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
WO2005095598A1 (ja) 2004-03-31 2005-10-13 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来の癌抗原ペプチド
WO2007097358A1 (ja) 2006-02-22 2007-08-30 International Institute Of Cancer Immunology, Inc. Ｈｌａ－ａ＊３３０３拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
"Peptide Synthesis", 1966, INTERSCIENCE
"Peptide-Gosei No Kiso To Jikken", 1985, MARUZEN CO., LTD.
"Peptide-Gosei", 1975, MARUZEN CO., LTD.
"Peptide-Gosei", vol. 14, 1991, HIROKAWA - BOOK STORE, article "Iyakuhin No Kaihatsu (Zoku)"
"The Proteins", vol. 2, 1976, ACADEMIC PRESS INC.
CALL KM ET AL., CELL., vol. 60, no. 3, 9 February 1990 (1990-02-09), pages 509 - 20
DANIEL A. HABER ET AL., CELL., vol. 61, no. 7, 29 June 1990 (1990-06-29), pages 1257 - 69
GAO FG ET AL., CANCER RES., vol. 62, no. 22, 15 November 2002 (2002-11-15), pages 6438 - 41
HURAL J.A. ET AL.: "Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation", J. IMMUNOL., vol. 169, no. 1, 2002, pages 557 - 565, XP009121186 *
HURAL JA ET AL., J IMMUNOL., vol. 169, no. 1, 1 July 2002 (2002-07-01), pages 557 - 65
INOUE K ET AL., BLOOD., vol. 91, no. 8, 15 April 1998 (1998-04-15), pages 2969 - 76
KNIGHTS AJ ET AL., CANCER IMMUNOL IMMUNOTHER., vol. 51, no. 5, July 2002 (2002-07-01), pages 271 - 81
MENKE AL ET AL., INT REV CYTOL., vol. 181, 1998, pages 151 - 212
OKA Y ET AL., IMMUNOGENETICS, vol. 51, no. 2, February 2000 (2000-02-01), pages 99 - 107
See also references of EP2119778A4
SOTIRIADOU R ET AL., BR J CANCER., vol. 85, no. 10, 16 November 2001 (2001-11-16), pages 1527 - 34
SOTIRIADOU R. ET AL.: "Peptide HER2 (776-788) represents a naturally processed broad MHC class II-restricted T cell epitope", BR. J. CANCER, vol. 85, no. 10, 2001, pages 1527 - 1534, XP002293865 *
TSUBOI A ET AL., LEUK RES., vol. 23, no. 5, May 1999 (1999-05-01), pages 499 - 505
YAMAGAMI T ET AL., BLOOD, vol. 87, no. 7, 1 April 1996 (1996-04-01), pages 2878 - 84
ZENG G, J IMMUNOTHER., vol. 24, no. 3, May 2001 (2001-05-01), pages 195 - 204

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11027003B2 (en) 2003-11-05 2021-06-08 International Institute Of Cancer Immunology, Inc. HLA-DR-binding antigen peptide derived from WT1
US10124046B2 (en) 2003-11-05 2018-11-13 International Institute Of Cancer Immunology, Inc. HLA-DR-binding antigen peptide derived from WT1
US11555814B2 (en) 2007-02-27 2023-01-17 International Institute Of Cancer Immunology, Inc. Method for activation of helper t cell and composition for use in the method
US10139395B2 (en) 2007-02-27 2018-11-27 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
US9266932B2 (en) 2009-04-23 2016-02-23 International Institute Of Cancer Immunology, Inc. Cancer antigen helper peptide
US11732018B2 (en) 2009-04-23 2023-08-22 International Institute Of Cancer Immunology, Inc. Cancer antigen helper peptide
CN102803487A (zh) * 2009-04-23 2012-11-28 株式会社癌免疫研究所 癌抗原辅助肽
US10759840B2 (en) 2009-04-23 2020-09-01 International Institute Of Cancer Immunology, Inc. Cancer antigen helper peptide
WO2010123065A1 (ja) * 2009-04-23 2010-10-28 株式会社癌免疫研究所 癌抗原ヘルパーペプチド
US10654892B2 (en) 2010-10-05 2020-05-19 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
KR20190034359A (ko) 2010-10-05 2019-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
US12415833B2 (en) 2010-10-05 2025-09-16 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
JP2017006120A (ja) * 2010-10-05 2017-01-12 株式会社癌免疫研究所 ヘルパーｔ細胞の活性化方法
JP6134139B2 (ja) * 2010-10-05 2017-05-24 株式会社癌免疫研究所 ヘルパーｔ細胞の活性化方法
WO2012046730A1 (ja) 2010-10-05 2012-04-12 国立大学法人大阪大学 ヘルパーｔ細胞の活性化方法
JP2018093870A (ja) * 2010-10-05 2018-06-21 株式会社癌免疫研究所 ヘルパーｔ細胞の活性化方法
EA037547B1 (ru) * 2010-10-05 2021-04-12 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Способ активации хелперных т-клеток
AU2011313327B2 (en) * 2010-10-05 2015-10-22 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
KR20200018738A (ko) 2010-10-05 2020-02-19 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
CN104797711A (zh) * 2012-09-12 2015-07-22 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
US20160009781A1 (en) 2012-09-12 2016-01-14 International Institute Of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
US10815288B2 (en) 2012-09-12 2020-10-27 International Institute Of Cancer Immunology, Inc. Antigen-specific helper T-cell receptor genes
EP3495483A1 (en) 2012-09-12 2019-06-12 International Institute of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
WO2014042226A1 (ja) 2012-09-12 2014-03-20 株式会社癌免疫研究所 抗原特異的ヘルパーｔ細胞レセプター遺伝子
US11091531B2 (en) 2012-09-12 2021-08-17 International Institute Of Cancer Immunology, Inc. Antigen-specific helper T-cell receptor genes
CN104797711B (zh) * 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
RU2680588C2 (ru) * 2012-09-12 2019-02-22 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Гены рецепторов антигенспецифичных хелперных т-клеток
US9833493B2 (en) 2012-12-17 2017-12-05 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
WO2014098012A1 (ja) 2012-12-17 2014-06-26 大塚製薬株式会社 ヘルパーt細胞の活性化方法
KR20150096697A (ko) 2012-12-17 2015-08-25 오츠카 세이야쿠 가부시키가이샤 헬퍼 t세포의 활성화 방법
WO2015129790A1 (ja) * 2014-02-26 2015-09-03 株式会社バイオイミュランス Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤
US10253075B2 (en) 2014-02-26 2019-04-09 tella, Inc. WT1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
JP6005305B2 (ja) * 2014-02-26 2016-10-12 テラ株式会社 Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤

Also Published As

Publication number Publication date
CN103088103A (zh) 2013-05-08
MX352947B (es) 2017-12-14
RU2014104572A (ru) 2015-08-20
JPWO2008105462A1 (ja) 2010-06-03
JP2013139448A (ja) 2013-07-18
NZ599161A (en) 2012-07-27
SI2119778T1 (sl) 2016-03-31
RU2009135802A (ru) 2011-04-10
CA2677075A1 (en) 2008-09-04
CN104312974B (zh) 2018-09-04
DK2119778T3 (en) 2016-01-25
SG177998A1 (en) 2012-02-28
IL200161A (en) 2015-11-30
HUE027472T2 (en) 2016-09-28
CN103103246B (zh) 2018-05-01
CN104312974A (zh) 2015-01-28
JP5714619B2 (ja) 2015-05-07
UA101608C2 (uk) 2013-04-25
CN103149366B (zh) 2018-06-15
US20200064332A1 (en) 2020-02-27
HRP20160020T1 (hr) 2016-02-12
NZ578721A (en) 2012-04-27
CY1117150T1 (el) 2017-04-05
US20100247556A1 (en) 2010-09-30
MY158219A (en) 2016-09-15
CN103088103B (zh) 2015-09-30
MX2009009168A (es) 2009-09-07
CN104774910A (zh) 2015-07-15
NZ599160A (en) 2012-07-27
ES2559062T3 (es) 2016-02-10
IL200161A0 (en) 2011-08-01
HK1138321A1 (en) 2010-08-20
CN101622344A (zh) 2010-01-06
BRPI0808084A2 (pt) 2014-07-22
KR20090125067A (ko) 2009-12-03
MY164867A (en) 2018-01-30
US11555814B2 (en) 2023-01-17
CA2677075C (en) 2018-07-10
US10139395B2 (en) 2018-11-27
JP5225262B2 (ja) 2013-07-03
AU2008220031A1 (en) 2008-09-04
CN104774910B (zh) 2018-04-10
CN103149366A (zh) 2013-06-12
EP2119778B1 (en) 2015-11-04
PL2119778T3 (pl) 2016-04-29
RU2680539C2 (ru) 2019-02-22
EP2119778A4 (en) 2010-08-18
ZA200905467B (en) 2010-05-26
KR101598228B1 (ko) 2016-02-26
EP2119778A1 (en) 2009-11-18
AU2008220031B2 (en) 2013-06-13
PT2119778E (pt) 2016-02-15
CN103103246A (zh) 2013-05-15

Similar Documents

Publication Publication Date Title
WO2008105462A1 (ja) ヘルパーｔ細胞の活性化方法およびそのための組成物
WO2007064857A3 (en) Amphoteric liposome formulation
GB2430367B (en) Ion binding polymers and uses thereof
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2008133722A3 (en) Anti human sclerostin antibodies
NZ609460A (en) Method for activating helper t cell
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2008118587A3 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
WO2007100905A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2007102149A3 (en) Hydrazido derivatives of hyaluronic acid
WO2009106831A3 (en) Pharmaceutical composition comprising naltrexone
PH12015501361A1 (en) Method for activating helper t cell
EP4327874A3 (en) 3,6-disubstituted xanthylium salts
WO2008022345A3 (en) Compositions and methods for inhibiting cytochrome p450
WO2009062576A3 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2007130822A3 (en) Mglur5 modulators iii
WO2008073863A3 (en) Preparation and utility of substituted allylamines
WO2008113770A3 (en) Anti-androgen peptides and uses thereof in cancer therapy
WO2010057647A3 (en) Methods and compositions for the diagnosis and treatment of diabetes
WO2009042194A3 (en) Methods of synthesis for therapeuthic anti-hiv peptides
WO2009126335A3 (en) Ant2 inhibitor compounds and methods of use thereof
WO2004073625A3 (en) Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof
JO3046B1 (ar) اشكال متعددة من 7- )] 3-كلورو-6و11-ثنائي هيدرو -6-ميثيل ثنائي بنزو [1, 2][f,c] ثيازبين-11-يل)امينو[ حمض هباتونك S,S- ثنائي أوكسيد وطرق لتصنيعها و استخدامها.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880006096.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08712039

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009501276

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 578721

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200161

Country of ref document: IL

Ref document number: 2008220031

Country of ref document: AU

Ref document number: 2677075

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008220031

Country of ref document: AU

Date of ref document: 20080227

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 4956/CHENP/2009

Country of ref document: IN

Ref document number: 12009501614

Country of ref document: PH

Ref document number: 1020097017594

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12449765

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/009168

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008712039

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09103858

Country of ref document: CO

Ref document number: 13165216

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2009135802

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0808084

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090827

WWW Wipo information: withdrawn in national office

Ref document number: 578721

Country of ref document: NZ